Appendix Cancer Clinical Trials

Find Appendix Cancer Clinical Trials Near You

Molecular Profiling for Tumor Characterization and Risk Stratification in Patients With Appendiceal Cancer

Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY

This study investigates integrated epigenetic and epitranscriptomic features of appendiceal cancer using archived tumor tissue specimens from the same patient cohort. The study includes DNA methylation profiling and m6A epitranscriptomic profiling to define molecular subtypes, evaluate associations with clinicopathologic features, and develop molecular risk scores for prognostic stratification. The primary goal is to determine whether DNA methylation- and m6A-based molecular features can complement conventional histopathologic grading and improve risk stratification.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Patients with histologically confirmed appendiceal adenocarcinoma or appendiceal cancer.

• Availability of archived tumor tissue suitable for molecular profiling.

• Availability of tissue for DNA methylation profiling, m6A epitranscriptomic profiling, or both.

• Availability of relevant clinicopathologic data.

• Availability of survival or follow-up information when applicable.

• Age 18 years or older at diagnosis or tissue collection.

Locations
United States
California
City of Hope Medical Center
RECRUITING
Duarte
Contact Information
Primary
Ajay Goel
ajgoel@coh.org
6262184673
Time Frame
Start Date: 2026-05-01
Estimated Completion Date: 2027-01-01
Participants
Target number of participants: 400
Treatments
Appendiceal Cancer Cohort
Patients with histologically confirmed appendiceal cancer whose archived tumor tissue specimens and clinicopathologic data are available for integrated DNA methylation and m6A epitranscriptomic profiling.
Benign Appendix Reference Cohort
Individuals with benign or normal appendix tissue specimens used as non-malignant reference samples for comparison of tumor-associated DNA methylation and m6A epitranscriptomic features.
Related Therapeutic Areas
Sponsors
Leads: City of Hope Medical Center

This content was sourced from clinicaltrials.gov